Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir

Association HGE CHU Bordeaux Sud73 enrolled

Overview

The purpose of the study is to 1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after Telaprevir treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Hepatitis C

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HCV mono-infected subjects * Age \> 18 years Exclusion Criteria: * HBV co-infection

Locations (1)

Hôpital du haut-Lévêque

Pessac, France

Outcomes

Primary Outcomes

virological resitance

Time frame: 12 weeks after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.